Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONCT Oncternal Therapeutics	$0.53	$0.53	$0.53 ▼ $7.79	$1.56M	1.18	87,408 shs	N/A
PRQR ProQR Therapeutics	$2.14 +0.6%	$1.78	$1.07 ▼ $4.62	$225.47M	0.36	654,962 shs	175,653 shs
SEOVF Sernova Biotherapeutics	$0.11 +1.7%	$0.13	$0.10 ▼ $0.26	$35.74M	1	32,348 shs	17,000 shs
WVE WAVE Life Sciences	$6.97 +3.3%	$6.71	$5.04 ▼ $16.74	$1.08B	-1.01	1.28 million shs	652,460 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONCT Oncternal Therapeutics	0.00%	0.00%	0.00%	0.00%	-92.53%
PRQR ProQR Therapeutics	+5.97%	-1.39%	+19.66%	+67.72%	+29.48%
SEOVF Sernova Biotherapeutics	-5.23%	-11.13%	-12.58%	-21.73%	-56.33%
WVE WAVE Life Sciences	+3.69%	-1.46%	+8.00%	+1.66%	+29.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ONCT Oncternal Therapeutics	1.6963 of 5 stars	3.1	0.0	0.0	0.0	1.0	0.8	1.3
PRQR ProQR Therapeutics	2.1361 of 5 stars	3.6	3.0	0.0	0.0	3.1	0.0	0.0
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	4.5504 of 5 stars	3.5	1.0	0.0	4.8	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ONCT Oncternal Therapeutics	2.25	Hold	$10.00	1,798.97% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	269.52% Upside
SEOVF Sernova Biotherapeutics	0.00	N/A	N/A	N/A
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.50	196.89% Upside

Current Analyst Ratings Breakdown

Latest WVE, PRQR, SEOVF, and ONCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/29/2025	WVE WAVE Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/8/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ONCT Oncternal Therapeutics	$790K	1.97	N/A	N/A	$10.19 per share	0.05
PRQR ProQR Therapeutics	$20.46M	11.13	N/A	N/A	$0.91 per share	2.38
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	($0.04) per share	N/A
WVE WAVE Life Sciences	$108.30M	9.92	N/A	N/A	$1.37 per share	5.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ONCT Oncternal Therapeutics	-$39.48M	-$11.69	N/A	N/A	N/A	-1,599.95%	-177.58%	-131.30%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
SEOVF Sernova Biotherapeutics	-$23.65M	-$0.04	N/A	∞	N/A	N/A	N/A	-396.49%	9/15/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/6/2025 (Estimated)

Latest WVE, PRQR, SEOVF, and ONCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q2 2025	SEOVF Sernova Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ONCT Oncternal Therapeutics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ONCT Oncternal Therapeutics	N/A	2.39	2.39
PRQR ProQR Therapeutics	N/A	4.10	4.10
SEOVF Sernova Biotherapeutics	N/A	0.12	0.12
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ONCT Oncternal Therapeutics	16.05%
PRQR ProQR Therapeutics	32.65%
SEOVF Sernova Biotherapeutics	N/A
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
ONCT Oncternal Therapeutics	11.20%
PRQR ProQR Therapeutics	8.40%
SEOVF Sernova Biotherapeutics	N/A
WVE WAVE Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ONCT Oncternal Therapeutics	30	2.96 million	2.63 million	No Data
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
SEOVF Sernova Biotherapeutics	N/A	328.48 million	N/A	Not Optionable
WVE WAVE Life Sciences	240	155.56 million	110.29 million	Optionable

WVE, PRQR, SEOVF, and ONCT Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Given Outperform Rating at Wedbush

June 24, 2025 | americanbankingnews.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

Wave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association Meeting

June 22, 2025 | nasdaq.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...

June 20, 2025 | finance.yahoo.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

June 20, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?

June 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in Stock

June 14, 2025 | insidertrades.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 Shares

June 13, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Now Covered by Raymond James

June 11, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

June 11, 2025 | marketbeat.com

Brokers Offer Predictions for WVE FY2026 Earnings

June 10, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's Why

June 9, 2025 | marketbeat.com

Two Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 3, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | msn.com

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

WAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of Earnings

May 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE, PRQR, SEOVF, and ONCT Company Descriptions

Oncternal Therapeutics NASDAQ:ONCT

$0.53 0.00 (0.00%)

As of 04/29/2025

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

ProQR Therapeutics NASDAQ:PRQR

$2.14 +0.01 (+0.52%)

As of 03:59 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.11 +0.00 (+1.68%)

As of 10:00 AM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

WAVE Life Sciences NASDAQ:WVE

$6.97 +0.22 (+3.26%)

Closing price 03:00 PM Eastern

Extended Trading

$6.97 0.00 (0.00%)

As of 04:14 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time